Novel exenatide analogs with peptidic albumin binding domains: Potent anti-diabetic agents with extended duration of action

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Levy, Odile E ^a   Jodka, Carolyn M ^a   Ren, Shijun Steven ^a   Mamedova, Lala ^a   Sharma, Abhinandini ^a   Samant, Manoj ^a   D'Souza, Lawrence J ^a   Soares, Christopher J ^a   Yuskin, Diane R ^a   Jin, Li Jenny ^a   Parkes, David G ^a   Tatarkiewicz, Krystyna ^a   Ghosh, Soumitra S ^a  

^a AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIDIABETIC AGENT; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LEUCINE; ALBUMINOID; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; PEPTIDE; PROTEIN BINDING; VENOM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; FEMALE; IN VITRO STUDY; MACACA FASCICULARIS; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PROTEIN BINDING; PROTEIN DOMAIN; WEIGHT REDUCTION; ANIMAL; BINDING SITE; CHEMISTRY; DISEASE MODEL; DRUG STABILITY; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE TOLERANCE TEST; HUMAN; KINETICS; MALE; METABOLISM; ORAL DRUG ADMINISTRATION; RAT;

ADMINISTRATION, ORAL; ALBUMINS; ANIMALS; BINDING SITES; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; DRUG STABILITY; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; KINETICS; MACACA FASCICULARIS; MALE; MICE; PEPTIDES; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; RATS; RECEPTORS, GLUCAGON; VENOMS;

EID: 84895198774     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087704     Document Type: Article

References (47)

1. Freda PU (2002) Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 87: 3013-3018.
2. Azria M, Copp DH, Zanelli JM (1995) 25 years of salmon calcitonin: from synthesis to therapeutic use. Calcif Tissue Int 57: 405-408.
3. Chesnut CH 3rd, Azria M, Silverman S, Engelhardt M, Olson M, et al. (2008) Salmon calcitonin: a review of current and future therapeutic indications. Osteoporos Int 19: 479-491.
4. Kraenzlin ME, Meier C (2011) Parathyroid hormone analogues in the treatment of osteoporosis. Nat Rev Endocrinol 7: 647-656.
5. Mannucci PM (1997) Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 90: 2515-2521.
6. Wallis K, Walters JR, Gabe S (2009) Short bowel syndrome: the role of GLP-2 on improving outcome. Curr Opin Clin Nutr Metab Care 12: 526-532.
7. Meibohm B, Zhou H (2012) Characterizing the impact of renal impairment on the clinical pharmacology of biologics. J Clin Pharmacol 52: 54S-62S.
8. Clark R, Olson K, Fuh G, Marian M, Mortensen D, et al. (1996) Long-acting growth hormones produced by conjugation with polyethylene glycol. J Biol Chem 271: 21969-21977. (Pubitemid 26303822)
9. Harris JM, Chess RB (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2: 214-221.
10. Lee LS, Conover C, Shi C, Whitlow M, Filpula D (1999) Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: a comparison of conjugation chemistries and compounds. Bioconjug Chem 10: 973-981.
11. Yamamoto Y, Tsutsumi Y, Yoshioka Y, Nishibata T, Kobayashi K, et al. (2003) Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity. Nat Biotechnol 21: 546-552. (Pubitemid 36532020)
12. Alters SE, McLaughlin B, Spink B, Lachinyan T, Wang CW, et al. (2012) GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn's disease model. PLoS One 7: e50630.
13. Schellenberger V, Wang CW, Geething NC, Spink BJ, Campbell A, et al. (2009) A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat Biotechnol 27: 1186-1190.
14. Ashkenazi A, Chamow SM (1997) Immunoadhesins as research tools and therapeutic agents. Curr Opin Immunol 9: 195-200. (Pubitemid 27190118)
15. Jazayeri JA, Carroll GJ (2008) Fc-based cytokines : prospects for engineering superior therapeutics. BioDrugs 22: 11-26. (Pubitemid 351158531)
16. Jimenez-Solem E, Rasmussen MH, Christensen M, Knop FK (2010) Dulaglu-tide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes. Curr Opin Mol Ther 12: 790-797.
17. Baggio LL, Huang Q, Brown TJ, Drucker DJ (2004) A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 53: 2492-2500. (Pubitemid 39145610)
18. Deacon CF (2009) Potential of liraglutide in the treatment of patients with type 2 diabetes. Vasc Health Risk Manag 5: 199-211.
19. Dennis MS, Zhang M, Meng YG, Kadkhodayan M, Kirchhofer D, et al. (2002) Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem 277: 35035-35043.
20. Kurtzhals P, Havelund S, Jonassen I, Kiehr B, Larsen UD, et al. (1995) Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J 312 (Pt 3): 725-731. (Pubitemid 26005980)
21. Markussen J, Havelund S, Kurtzhals P, Andersen AS, Halstrom J, et al. (1996) Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 39: 281-288. (Pubitemid 26064823)
22. Andersen JT, Sandlie I (2009) The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics. Drug Metab Pharmacokinet 24: 318-332.
23. Anderson CL, Chaudhury C, Kim J, Bronson CL, Wani MA, et al. (2006) Perspective- FcRn transports albumin: relevance to immunology and medicine. Trends Immunol 27: 343-348. (Pubitemid 43963476)
24. Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7: 715-725. (Pubitemid 47327396)
25. McCurdy TR, Gataiance S, Eltringham-Smith LJ, Sheffield WP (2004) A covalently linked recombinant albumin dimer is more rapidly cleared in vivo than are wild-type and mutant C34A albumin. J Lab Clin Med 143: 115-124. (Pubitemid 38241563)
26. Havelund S, Plum A, Ribel U, Jonassen I, Volund A, et al. (2004) The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 21: 1498-1504. (Pubitemid 39149667)
27. Keating GM (2012) Insulin detemir: a review of its use in the management of diabetes mellitus. Drugs 72: 2255-2287.
28. Baruah MP, Chaudhury T, Sethi BK, Dharmalingam M (2012) Liraglutide in type 2 diabetes mellitus. J Indian Med Assoc 110: 335-338.
29. Knudsen LB (2010) Liraglutide: the therapeutic promise from animal models. Int J Clin Pract Suppl: 4-11.
30. de Chateau M, Bjorck L (1994) Protein PAB, a mosaic albumin-binding bacterial protein representing the first contemporary example of module shuffling. J Biol Chem 269: 12147-12151.
31. Lejon S, Frick IM, Bjorck L, Wikstrom M, Svensson S (2004) Crystal structure and biological implications of a bacterial albumin binding module in complex with human serum albumin. J Biol Chem 279: 42924-42928. (Pubitemid 39372183)
32. Johansson MU, Frick IM, Nilsson H, Kraulis PJ, Hober S, et al. (2002) Structure, specificity, and mode of interaction for bacterial albumin-binding modules. J Biol Chem 277: 8114-8120. (Pubitemid 34975650)
33. Jonsson A, Dogan J, Herne N, Abrahmsen L, Nygren PA (2008) Engineering of a femtomolar affinity binding protein to human serum albumin. Protein Eng Des Sel 21: 515-527. (Pubitemid 352019923)
34. Linhult M, Binz HK, Uhlen M, Hober S (2002) Mutational analysis of the interaction between albumin-binding domain from streptococcal protein G and human serum albumin. Protein Sci 11: 206-213. (Pubitemid 34075783)
35. Andersen JT, Pehrson R, Tolmachev V, Daba MB, Abrahmsen L, et al. (2011) Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain. J Biol Chem 286: 5234-5241.
36. Hargrove DM, Kendall ES, Reynolds JM, Lwin AN, Herich JP, et al. (2007) Biological activity of AC3174, a peptide analog of exendin-4. Regul Pept 141: 113-119. (Pubitemid 46482688)
37. Fineman M, Flanagan S, Taylor K, Aisporna M, Shen LZ, et al. (2011) Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet 50: 65-74.
38. Mack CM, Moore CX, Jodka CM, Bhavsar S, Wilson JK, et al. (2006) Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. Int J Obes (Lond) 30: 1332-1340. (Pubitemid 44306514)
39. Knudsen LB (2004) Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes. J Med Chem 47: 4128-4134.
40. Dharmalingam M, Sriram U, Baruah MP (2011) Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus. Indian J Endocrinol Metab 15: 9-17.
41. Sturis J, Gotfredsen CF, Romer J, Rolin B, Ribel U, et al. (2003) GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol 140: 123-132. (Pubitemid 37175838)
42. Thorens B, Porret A, Buhler L, Deng SP, Morel P, et al. (1993) Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 42: 1678-1682. (Pubitemid 23318127)
43. Raufman JP (1996) Bioactive peptides from lizard venoms. Regul Pept 61: 1-18.
44. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, et al. (1999) Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 48: 1026-1034. (Pubitemid 29226349)
45. Nelson-Piercy C, Hammond PJ, Gwilliam ME, Khandan-Nia N, Myers MJ, et al. (1994) Effect of a new oral somatostatin analog (SDZ CO 611) on gastric emptying, mouth to cecum transit time, and pancreatic and gut hormone release in normal male subjects. J Clin Endocrinol Metab 78: 329-336. (Pubitemid 24061749)
46. Henriksen K, Bay-Jensen AC, Christiansen C, Karsdal MA (2010) Oral salmon calcitonin-pharmacology in osteoporosis. Expert Opin Biol Ther 10: 1617-1629.
47. Eldor R, Arbit E, Corcos A, Kidron M (2013) Glucose-Reducing Effect of the ORMD-0801 Oral Insulin Preparation in Patients with Uncontrolled Type 1 Diabetes: A Pilot Study. PLoS One 8: e59524.